300896 Stock Overview
Imeik Technology Development Co.,Ltd focuses on the research and development, production, and sale of biomedical materials.
Imeik Technology DevelopmentLtd Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CN¥547.24|
|52 Week High||CN¥844.44|
|52 Week Low||CN¥391.09|
|1 Month Change||12.37%|
|3 Month Change||21.66%|
|1 Year Change||-20.71%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||189.63%|
Recent News & Updates
|300896||CN Biotechs||CN Market|
Return vs Industry: 300896 exceeded the CN Biotechs industry which returned -32.7% over the past year.
Return vs Market: 300896 underperformed the CN Market which returned -10.6% over the past year.
|300896 Average Weekly Movement||6.8%|
|Biotechs Industry Average Movement||7.2%|
|Market Average Movement||7.1%|
|10% most volatile stocks in CN Market||10.1%|
|10% least volatile stocks in CN Market||5.0%|
Stable Share Price: 300896 is not significantly more volatile than the rest of CN stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: 300896's weekly volatility (7%) has been stable over the past year.
About the Company
Imeik Technology Development Co.,Ltd focuses on the research and development, production, and sale of biomedical materials. The company offers medical beauty field products, including Moisten Angel, IFRESH, Yimei, Hearty, Bonita Bonita, and Tightly. It also offers skin care products, including moisturizing lotions, anti-wrinkle firming kinetic energy liquids, essence creams, hydrating firming masks, chitosan B5 repair sprays, and purifying and brightening kinetic liquids.
Imeik Technology DevelopmentLtd Fundamentals Summary
|300896 fundamental statistics|
Is 300896 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|300896 income statement (TTM)|
|Cost of Revenue||CN¥95.73m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||4.93|
|Net Profit Margin||65.90%|
How did 300896 perform over the long term?See historical performance and comparison
0.4%Current Dividend Yield
Is 300896 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 300896?
Other financial metrics that can be useful for relative valuation.
|What is 300896's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 300896's PE Ratio compare to its peers?
|300896 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
Price-To-Earnings vs Peers: 300896 is expensive based on its Price-To-Earnings Ratio (111x) compared to the peer average (78.6x).
Price to Earnings Ratio vs Industry
How does 300896's PE Ratio compare vs other companies in the Chinese Biotechs Industry?
Price-To-Earnings vs Industry: 300896 is expensive based on its Price-To-Earnings Ratio (111x) compared to the CN Biotechs industry average (38.7x)
Price to Earnings Ratio vs Fair Ratio
What is 300896's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||111x|
|Fair PE Ratio||47.9x|
Price-To-Earnings vs Fair Ratio: 300896 is expensive based on its Price-To-Earnings Ratio (111x) compared to the estimated Fair Price-To-Earnings Ratio (47.9x).
Share Price vs Fair Value
What is the Fair Price of 300896 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 300896 (CN¥547.24) is trading above our estimate of fair value (CN¥319.02)
Significantly Below Fair Value: 300896 is trading above our estimate of fair value.
Price to Earnings Growth Ratio
PEG Ratio: 300896 is poor value based on its PEG Ratio (2.9x)
Discover undervalued companies
How is Imeik Technology DevelopmentLtd forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
Future Growth Score6/6
Future Growth Score 6/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 300896's forecast earnings growth (37.8% per year) is above the savings rate (3.3%).
Earnings vs Market: 300896's earnings (37.8% per year) are forecast to grow faster than the CN market (23.9% per year).
High Growth Earnings: 300896's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 300896's revenue (39.6% per year) is forecast to grow faster than the CN market (17.4% per year).
High Growth Revenue: 300896's revenue (39.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 300896's Return on Equity is forecast to be high in 3 years time (28.6%)
Discover growth companies
How has Imeik Technology DevelopmentLtd performed over the past 5 years?
Past Performance Score6/6
Past Performance Score 6/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 300896 has high quality earnings.
Growing Profit Margin: 300896's current net profit margins (65.9%) are higher than last year (63.8%).
Past Earnings Growth Analysis
Earnings Trend: 300896's earnings have grown significantly by 42.3% per year over the past 5 years.
Accelerating Growth: 300896's earnings growth over the past year (88.1%) exceeds its 5-year average (42.3% per year).
Earnings vs Industry: 300896 earnings growth over the past year (88.1%) exceeded the Biotechs industry 11.3%.
Return on Equity
High ROE: 300896's Return on Equity (20.2%) is considered high.
Discover strong past performing companies
How is Imeik Technology DevelopmentLtd's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 300896's short term assets (CN¥4.0B) exceed its short term liabilities (CN¥149.4M).
Long Term Liabilities: 300896's short term assets (CN¥4.0B) exceed its long term liabilities (CN¥80.1M).
Debt to Equity History and Analysis
Debt Level: 300896 has more cash than its total debt.
Reducing Debt: 300896's debt to equity ratio has reduced from 1% to 0.2% over the past 5 years.
Debt Coverage: 300896's debt is well covered by operating cash flow (9083%).
Interest Coverage: 300896 earns more interest than it pays, so coverage of interest payments is not a concern.
Discover healthy companies
What is Imeik Technology DevelopmentLtd current dividend yield, its reliability and sustainability?
Dividend Score 2/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 300896's dividend (0.38%) isn’t notable compared to the bottom 25% of dividend payers in the CN market (0.49%).
High Dividend: 300896's dividend (0.38%) is low compared to the top 25% of dividend payers in the CN market (1.97%).
Stability and Growth of Payments
Stable Dividend: Too early to tell whether 300896's dividend payments have been stable as they only just started paying a dividend.
Growing Dividend: Too early to tell if 300896's dividend payments are increasing as they only just started paying a dividend.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (42.6%), 300896's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (45.5%), 300896's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Yifeng Shi (48 yo)
Mr. Shi Yifeng serves as Director and General Manager at Imeik Technology Development Co.,Ltd.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Imeik Technology Development Co.,Ltd.'s employee growth, exchange listings and data sources
- Name: Imeik Technology Development Co.,Ltd.
- Ticker: 300896
- Exchange: SZSE
- Founded: 2004
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: CN¥118.401b
- Shares outstanding: 216.36m
- Website: https://www.imeik.net
Number of Employees
- Imeik Technology Development Co.,Ltd.
- Shimao Building
- Floor 21st, Block C
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/22 00:00|
|End of Day Share Price||2022/06/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.